Intelligence Briefing · ~5 min read
TEVA's ANDA219413 Submission Signals Potential Market Disruption
Not specified
Type
Regulatory Context BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
6
Key Takeaways
Leadership-ready summary — read in 5 minutes.
- Regulatory risk is concentrated around FDA TA — ANDA219413 (FDA). Entity match (teva pharmaceuticals inc); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for FDA evaluation, which could affect the timing of market entry for this generic product.
- Elevated medium regulatory exposure for TEVA PHARMACEUTICALS, INC could delay market entry or constrain labeling if agency review intensifies.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Regulatory risk is concentrated around FDA TA — ANDA219413 (FDA). Entity match (teva pharmaceuticals inc); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for FDA evaluation, which could affect the timing of market entry for this generic product.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
TEVA Pharmaceuticals submits ANDA219413 for FDA review
Not specified
Source: Regulatory Approval
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.